Cheng Fang¹, Changping Wu² 

¹Department of Oncology,Third Affiliated Hospital of Soochow University, ²Department of Tumor Biological Treatment, Third Affiliated Hospital of Soochow University.

Objective:Lenalidomide has been shown to producedurable responses in patients with relapsed or refractory diffuse large B celllymphoma (DLBCL). In order to gain better understanding of the efficacy oflenalidomide and compared the difference in clinical outcome between twosubtypes of DLBCL. Method: Seven eligible trials involving 375 adultpatients were included in this meta-analysis. Result: The patients innon-germinal center B-cell (non-GCB) subtype had higher overall response (OR)rate compared with GCB patients (P=0.21). In subgroup analysis, asfirst-line and second-line treatment for DLBCL patient, GCB DLBCL did not showsignificantly better outcome compared with non-GCB subtype patients (P=0.96;P=0.27). More importantly, after lenalidomide treatment, the patientswith non-GCB DLBCL did not show significantly worse progression-free survival(PFS) and overall survival (OS) compared with GCB subtype. Conclusion: Lenalidomideas treatments for DLBCL patients, non-GCB DLBCL patients did not showsignificantly worse prognosis compared with GCB DLBCL.

Key Words: Diffuse large B celllymphoma  lenalidomide